Phase II trial of combined chemotherapy with irinotecan, S-1, and bevacizumab (IRIS/Bev) in patients with metastatic colorectal cancer: Update analysis—Hokkaido Gastrointestinal Cancer Study Group (HGCSG) trial.

Authors

Satoshi Yuki

Department of Gastroenterology, Hokkaido University Hospital, Sapporo, Japan

Satoshi Yuki , Yoshito Komatsu , Takuto Miyagishima , Takashi Kato , Kazuteru Hatanaka , Michio Nakamura , Mineo Kudo , Nobuaki Akakura , Miki Tateyama , Yuh Sakata

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2013 Gastrointestinal Cancers Symposium

bookmark_border

Phase II trial of combined chemotherapy with irinotecan, S-1, and bevacizumab (IRIS/Bev) in patients with metastatic colorectal cancer (mCRC): Final analysis—Hokkaido Gastrointestinal Cancer Study Group (HGCSG) trial.

First Author: Satoshi Yuki

insert_chart_outlined

Poster

2016 Gastrointestinal Cancers Symposium

bookmark_border

A phase II study of bevacizumab in combination with irinotecan plus S-1 as first-line treatment in patients with KRAS mutant-type metastatic colorectal cancer.

First Author: Tetsuya Eto

insert_chart_outlined

Poster

2016 Gastrointestinal Cancers Symposium

bookmark_border

Bevacizumab effectiveness and primary tumor location in metastatic colorectal cancer patients.

First Author: Wen-zhuo He

insert_chart_outlined

Poster

2013 ASCO Annual Meeting

bookmark_border

SPIRITT (study 20060141): A randomized phase II study of FOLFIRI with either panitumumab (pmab) or bevacizumab (bev) as second-line treatment (tx) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC).

First Author: Allen Lee Cohn